Dr. Stephen J. Freedland spoke at the 25th International Prostate Cancer Update on Friday, January 23, 2015 on “Biochemical Failure After Treatment.”

Presentation 

 

Keywords: PSA recurrence, risk stratification, hormonal therapy

How to cite: Freedland, Stephen J. “Biochemical Failure After Treatment” Grand Rounds in Urology. April 13, 2015. Accessed Mar 2024. https://grandroundsinurology.com/prostate-cancer-stephen-j-freedland-biochemical-failure-after-treatment/.

References

References

D’Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003 Sep 17;95(18):1376-83.
http://www.ncbi.nlm.nih.gov/pubmed/13130113

Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005 Jul 27;294(4):433-9.
http://www.ncbi.nlm.nih.gov/pubmed/16046649

Heidenreich A, Abrahamsson PA, Artibani W, et al. Early detection of prostate cancer: European Association of Urology recommendation. Eur Urol. 2013 Sep;64(3):347-54
http://www.ncbi.nlm.nih.gov/pubmed/23856038

Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007 Apr 20;25(12):1596-605.
http://www.ncbi.nlm.nih.gov/pubmed/17404365

Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999 May 5;281(17):1591-7.
http://www.ncbi.nlm.nih.gov/pubmed/10235151

Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008 Jun 18;299(23):2760-9.
http://www.ncbi.nlm.nih.gov/pubmed/18560003